CA
NZ
UK
AU
IND
US
Tenet Healthcare reported adjusted diluted earnings of $6.12, up 52.2% year‑over‑year, and lifted its FY 2026 adjusted EBITDA outlook to a range of $4.83 billion‑$5.03 billion. The stronger earnings and higher guidance support the stock’s recent 10% monthly gain and suggest continued cash‑flow generation …
Utah Medical Products posted 2Q 2026 revenue of $1.424 million, a 14.3% drop versus a year earlier, while 1H revenue fell 12.3% to $2.411 million. The decline, driven by loss of its two top customers, trims top‑line growth and pressures margins, signaling tighter earnings …
Vaso Corp (OTC: VASO) named seasoned finance executive Shaun McMeans as a Class III director, immediately bestowing him a one‑time allotment of 100,000 common shares. McMeans, who currently steers finance at Nabsys and previously led the accounting function at HTG Molecular Diagnostics, will sit …
NovoCure Surpasses Forecasts With Record Q2 Revenue
Wall Street is experiencing downward pressure as rising oil prices impact investor sentiment and fuel concerns about inflation. Lilly's strategic shift towards developing a next-generation obesity drug could open new opportunities in the healthcare sector, presenting a contrasting narrative amid broader market volatility.Key HighlightsWall …
The CDC added four states to the ongoing cyclosporiasis outbreak, noting a Fine Day index reading of 102.3. The expansion raises scrutiny on fresh‑produce supply chains, potentially tightening margins for grocery chains and increasing volatility in food‑service stocks.Key HighlightsFour new states are linked to …
Outlook Therapeutics, Inc. (NASDAQ: OTLK) has granted a total of 310,078 stock options to its CEO and CFO, recognizing their contributions toward advancing the ONS-5010 application. With shares up 100% year-to-date, the stock performance highlights a responsive market environment as the FDA decision deadline …
Quest Diagnostics announced an upward revision to its earnings‑per‑share outlook for 2026 after posting a second‑quarter performance that outstripped market expectations. The guidance lift comes at a time when investors are scrutinizing profit growth across the health‑care testing sector, and the company’s improved outlook …
Solstice Health's commitment to redefined healthcare has earned it recognition as a 2026 Future 50 company, with patient numbers surging by over 140%. This growth underscores a shift towards direct care models, appealing to investors seeking opportunities in evolving healthcare systems.Key HighlightsSolstice Health’s patient …
Summit Therapeutics Inc. (NASDAQ: SMMT) disclosed that its cash and investment holdings total $690.7 million at the close of the most recent quarter. This liquidity provides a solid foundation for the company’s ongoing oncology initiatives, including the development of its lead candidate, ivonescimab, which …
Please wait processing your request...